Zealand Pharma wants to buy access to the US market through bankrupt firm

Zealand Pharma's bid on bankrupt medtech company Valeritas is an attempt to buy a shortcut into the US market by taking over a fully functional commercial organization in the country.

Emmanuel Dulac, CEO of Zealand Pharma Photo: Zealand Pharma/ PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles